Janus Henderson Group PLC Sells 82,283 Shares of STAAR Surgical Company $STAA

Janus Henderson Group PLC lowered its stake in STAAR Surgical Company (NASDAQ:STAA) by 38.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 130,404 shares of the medical instruments supplier’s stock after selling 82,283 shares during the period. Janus Henderson Group PLC’s holdings in STAAR Surgical were worth $2,441,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Broadwood Capital Inc. lifted its position in STAAR Surgical by 11.1% in the fourth quarter. Broadwood Capital Inc. now owns 15,019,491 shares of the medical instruments supplier’s stock valued at $346,800,000 after purchasing an additional 1,500,000 shares during the last quarter. Soleus Capital Management L.P. grew its holdings in shares of STAAR Surgical by 16.5% in the second quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier’s stock worth $50,084,000 after purchasing an additional 421,840 shares during the last quarter. Yunqi Capital Ltd increased its stake in shares of STAAR Surgical by 0.3% in the fourth quarter. Yunqi Capital Ltd now owns 2,507,130 shares of the medical instruments supplier’s stock worth $57,890,000 after buying an additional 7,069 shares during the period. Magnetar Financial LLC raised its holdings in STAAR Surgical by 105.3% during the 4th quarter. Magnetar Financial LLC now owns 2,472,390 shares of the medical instruments supplier’s stock valued at $57,087,000 after buying an additional 1,268,019 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in STAAR Surgical by 112.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,076,743 shares of the medical instruments supplier’s stock valued at $47,952,000 after buying an additional 1,100,484 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on STAA shares. Piper Sandler raised their price target on shares of STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Wedbush reiterated an “outperform” rating and set a $40.00 target price on shares of STAAR Surgical in a report on Tuesday, August 4th. Wall Street Zen lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Zacks Research upgraded STAAR Surgical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Finally, Mizuho lifted their price objective on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $26.94.

STAAR Surgical Price Performance

STAA stock opened at $24.21 on Friday. STAAR Surgical Company has a 1 year low of $15.59 and a 1 year high of $35.87. The company has a market cap of $1.21 billion, a P/E ratio of -56.30 and a beta of 1.26. The firm has a 50-day moving average of $27.19 and a 200 day moving average of $23.96. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.12 and a quick ratio of 4.31.

STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. During the same quarter last year, the business posted ($1.10) EPS. The firm’s revenue for the quarter was up 119.6% compared to the same quarter last year. On average, sell-side analysts forecast that STAAR Surgical Company will post 0.13 EPS for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.